Novel approaches to tuberculosis vaccine development

Global tuberculosis report (2014)

Gabbasova, L. A., & Who, E. R. E. (2014) · Cited by 12,702 · see citing works

Efficacy of BCG Vaccine in the Prevention of Tuberculosis

Colditz, G. A. (1994) · JAMA · doi:10.1001/jama.1994.03510330076038 · Cited by 1,944 · see citing works

The spectrum of latent tuberculosis: rethinking the biology and intervention strategies

Barry, C. E., Boshoff, H. I., Dartois, V. A., Dick, T., Ehrt, S., Flynn, J. L., Schnappinger, D., Wilkinson, R. J., & Young, D. B. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2236 · Cited by 1,424 · see citing works

Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial

Tameris, M. D., Hatherill, M., Landry, B., Scriba, T. J., Snowden, M. A., Lockhart, S. P., Shea, J. E., McClain, J. B., Hussey, G. D., Hanekom, W. A., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60177-4 · Cited by 1,051 · see citing works

A blood RNA signature for tuberculosis disease risk: a prospective cohort study

Zak, D. E., Penn‐Nicholson, A., Scriba, T. J., Thompson, E. G., Suliman, S., Amon, L. M., Mahomed, H., Erasmus, M., Whatney, W. E., Hussey, G. D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01316-1 · Cited by 779 · see citing works

The Efficacy of Bacillus Calmette-Guerin Vaccination of Newborns and Infants in the Prevention of Tuberculosis: Meta-Analyses of the Published Literature

Colditz, G. A., Berkey, C. S., Mosteller, F. C., Brewer, T. F., Wilson, M. E., Burdick, E., & Fineberg, H. V. (1995) · PEDIATRICS · doi:10.1542/peds.96.1.29 · Cited by 759 · see citing works

Mycobacterium tuberculosis: success through dormancy

Gengenbacher, M., & Kaufmann, S. H. E. (2012) · FEMS Microbiology Reviews · doi:10.1111/j.1574-6976.2012.00331.x · Cited by 698 · see citing works

Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis

Roy, A., Eisenhut, M., Harris, R., Rodrigues, L. C., Sridhar, S., Habermann, S., Snell, L. B., Mangtani, P., Adetifa, I., Lalvani, A., et al. (2014) · BMJ · doi:10.1136/bmj.g4643 · Cited by 586 · see citing works

Vaccines against Tuberculosis: Where Are We and Where Do We Need to Go?

Ottenhoff, T. H. M., & Kaufmann, S. H. E. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002607 · Cited by 455 · see citing works

New insights into the function of granulomas in human tuberculosis

Ulrichs, T., & Kaufmann, S. H. E. (2006) · Journal of Pathology · doi:10.1002/path.1906 · Cited by 421 · see citing works

CD4 T Cell-Derived IFN-γ Plays a Minimal Role in Control of Pulmonary Mycobacterium tuberculosis Infection and Must Be Actively Repressed by PD-1 to Prevent Lethal Disease

Sakai, S., Kauffman, K. D., Sallin, M. A., Sharpe, A. H., Young, H. A., Ganusov, V. V., & Barber, D. L. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005667 · Cited by 349 · see citing works

Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics

Abu-Raddad, L. J., Sabatelli, L., Achterberg, J. T., Sugimoto, J. D., Longini, I. M., Dye, C., & Halloran, M. E. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0901720106 · Cited by 348 · see citing works

A Defined Tuberculosis Vaccine Candidate Boosts BCG and Protects Against Multidrug-Resistant Mycobacterium tuberculosis

Bertholet, S., Ireton, G. C., Ordway, D. J., Windish, H. P., Pine, S. O., Kahn, M., Phan, T., Orme, I. M., Vedvick, T. S., Baldwin, S. L., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001094 · Cited by 304 · see citing works

Effect of BCG vaccination on risk of Mycobacterium tuberculosis infection in children with household tuberculosis contact: a prospective community-based study

Soysal, A., Millington, K. A., Bakır, M., Dosanjh, D. P. S., Aslan, Y., Deeks, J. J., Efe, S., Staveley, I., Ewer, K., & Lalvani, A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67534-4 · Cited by 288 · see citing works

A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human

van Dissel, J. T., Joosten, S. A., Hoff, S. T., Soonawala, D., Prins, C., Hokey, D. A., O’Dee, D. M., Graves, A. J., Thierry-Carstensen, B., Andreasen, L. V., et al. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.10.036 · Cited by 245 · see citing works

Prevention of tuberculosis in Bacille Calmette–Guérin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine

von Reyn, C. F., Mtei, L., Arbeit, R. D., Waddell, R. D., Cole, B. F., MacKenzie, T. A., Matee, M. I., Bakari, M., Tvaroha, S., Adams, L. V., et al. (2010) · AIDS · doi:10.1097/qad.0b013e3283350f1b · Cited by 219 · see citing works

A Human Type 5 Adenovirus–Based Tuberculosis Vaccine Induces Robust T Cell Responses in Humans Despite Preexisting Anti-Adenovirus Immunity

Smaill, F., Jeyanathan, M., Smieja, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006843 · Cited by 204 · see citing works

Ag85B–ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers

van Dissel, J. T., Arend, S. M., Prins, C., Bang, P. F., Tingskov, P. N., Lingnau, K., Nouta, J., Klein, M. R., Rosenkrands, I., Ottenhoff, T. H. M., et al. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.02.094 · Cited by 203 · see citing works

Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial

Grode, L., Ganoza, C. A., Brohm, C., Weiner, J. M., Eisele, B., & Kaufmann, S. H. E. (2013) · Vaccine · doi:10.1016/j.vaccine.2012.12.053 · Cited by 196 · see citing works

First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults

Luabeya, A. K. K., Kagina, B. M. N., Tameris, M. D., Geldenhuys, H. D., Hoff, S. T., Shi, Z., Kromann, I., Hatherill, M., Mahomed, H., Hanekom, W. A., et al. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.06.051 · Cited by 194 · see citing works

Epidemiology: A mortal foe

Paulson, T. (2013) · Nature · doi:10.1038/502s2a · Cited by 188 · see citing works

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial

Satti, I., Meyer, J., Harris, S. A., et al. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70845-x · Cited by 177 · see citing works

Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial

Spertini, F., Audran, R., Chakour, R., et al. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00435-x · Cited by 177 · see citing works

Future Vaccination Strategies against Tuberculosis: Thinking outside the Box

Kaufmann, S. H. E. (2010) · Immunity · doi:10.1016/j.immuni.2010.09.015 · Cited by 166 · see citing works

Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting

Penn‐Nicholson, A., Geldenhuys, H. D., Burny, W., et al. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.05.088 · Cited by 139 · see citing works

Tuberculosis vaccines: Time to think about the next generation

Kaufmann, S. H. E. (2013) · Seminars in Immunology · doi:10.1016/j.smim.2013.04.006 · Cited by 138 · see citing works

Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI: Randomized, Placebo-Controlled Phase II Clinical Trial in Patients with Latent Tuberculosis Infection

Nell, A. S., D’lom, E., Bouic, P. J., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089612 · Cited by 136 · see citing works

Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A

Stylianou, E., Griffiths, K., Poyntz, H., et al. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.10.017 · Cited by 112 · see citing works

Recent advances towards tuberculosis control: vaccines and biomarkers

Weiner, J. M., & Kaufmann, S. H. E. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12212 · Cited by 91 · see citing works

The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial

Geldenhuys, H. D., Mearns, H., Miles, D. J. C., Tameris, M. D., Hokey, D. A., Shi, Z., Bennett, S. R., Andersen, P. L., Kromann, I., Hoff, S. T., et al. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.05.036 · Cited by 81 · see citing works

Tuberculosis vaccines: Time for a global strategy

Kaufmann, S. H. E., Evans, T. G., & Hanekom, W. A. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4730 · Cited by 68 · see citing works

From bacteriology to immunology: the dualism of specificity

Kaufmann, S. H. E., & Winau, F. (2005) · Nature Immunology · doi:10.1038/ni1105-1063 · Cited by 62 · see citing works

The effectiveness of BCG vaccination in preventing Mycobacterium tuberculosis infection and disease in Greenland

Michelsen, S. W., Søborg, B., Koch, A., Carstensen, L., Hoff, S. T., Agger, E. M., Lillebæk, T., Sørensen, H., Wohlfahrt, J., & Melbye, M. (2014) · Thorax · doi:10.1136/thoraxjnl-2014-205688 · Cited by 59 · see citing works

Vaccination Against Tuberculosis With Whole-Cell Mycobacterial Vaccines

Scriba, T. J., Kaufmann, S. H. E., Lambert, P. H., Sanicas, M., Martı́n, C., & Neyrolles, O. (2016) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiw228 · Cited by 59 · see citing works

Viral Replication Protein Inhibits Cellular Cofilin Actin Depolymerization Factor to Regulate the Actin Network and Promote Viral Replicase Assembly

Nawaz‐ul‐Rehman, M. S., Prasanth, K. R., Xu, K., Sasvári, Z., Kovalev, N., de Castro, I. F., Barajas, D., Risco, C., & Nagy, P. D. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005440 · Cited by 56 · see citing works

A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults

Minhinnick, A., Satti, I., Harris, S. A., et al. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.01.062 · Cited by 44 · see citing works

Excessive Cytolytic Responses Predict Tuberculosis Relapse After Apparently Successful Treatment

Cliff, J. M., Cho, J.-E., Lee, J., Ronacher, K., King, E. C., van Helden, P. D., Walzl, G., & Dockrell, H. M. (2015) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiv447 · Cited by 39 · see citing works

Adjunctive therapy of Mycobacterium vaccae vaccine in the treatment of multidrug-resistant tuberculosis: A systematic review and meta-analysis

Weng, H., Huang, J., Meng, X., et al. (2016) · Biomedical Reports · doi:10.3892/br.2016.624 · Cited by 35 · see citing works

Vaccination Against Tuberculosis with Nonliving Vaccines

Weiss, D. W. (1959) · American Review of Respiratory Disease · doi:10.1164/arrd.1959.80.5.676 · Cited by 32 · see citing works

Vaccination against tuberculosis with nonliving vaccines. I. The problem and its historical background.

Weiss, D. W. (1959) · PubMed · doi:10.1164/arrd.1959.80.3.340 · Cited by 28 · see citing works

Post-exposure vaccination with the vaccine candidate Bacillus Calmette–Guérin ΔureC::hly induces superior protection in a mouse model of subclinical tuberculosis

Gengenbacher, M., Kaiser, P., Schuerer, S., et al. (2016) · Microbes and Infection · doi:10.1016/j.micinf.2016.03.005 · Cited by 25 · see citing works

Addition of Mycobacterium indicus pranii vaccine as an immunotherapeutic to standard chemotherapy in borderline leprosy: a double-blind study to assess clinical improvement (preliminary report)

Kamal, R. S., Pathak, V. K., Kumari, A., et al. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14971 · Cited by 20 · see citing works

PROTECTIVE INOCULATION AGAINST HUMAN TUBERCULOSIS WITH HEAT-KILLED TUBERCLE BACILLI1

Opie, E. L., Flahiff, E. W., & Smith, H. (1939) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a118486 · Cited by 16 · see citing works

Heterologous prime-boost with Ad35/AERAS-402 and MVA85A elicits potent CD8+ T cell immune responses in a phase I clinical trial (VAC7P.969)

Hokey, D. A., O’Dee, D. M., Graves, A. J., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.192.supp.141.14 · Cited by 7 · see citing works

Developing vaccines to prevent sustained infection with Mycobacterium tuberculosis : Conference proceedings

Vaccine Prevention of Sustained Mycobacterium tuberculosis Infection Summary Group (2015) · Vaccine · doi:10.1016/j.vaccine.2015.03.061 · Cited by 6 · see citing works

Nanotechnology approaches for global infectious diseases

Kirtane, A. R., Verma, M., Karandikar, P., Furin, J., Langer, R., & Traverso, G. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00866-8 · Cited by 520 · see citing works

Simulation Analysis of the Impact of Vaccination on the Spread of Infectious Disease

Xiao-don, M. (2014) · Liaoning Yixueyuan xuebao

Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials

Arbués, A., Aguilo, J. I., Gonzalo‐Asensio, J., Marinova, D., Uranga, S., Puentes, E., Fernandez, C., Parra, A., Cardona, P.-J., Vilaplana, C., et al. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.07.051 · Cited by 256 · see citing works

[BCG vaccination: where are we now?].

Yavuz, T., Arbak, P., Öztürk, C. E., et al. (2004) · PubMed · Cited by 2 · see citing works

BCG vaccination induration size as an indicator of infection with mycobacterium tuberculosis

Gothi, G. D., Nair, S., Bhushan, K., et al. (1974) · Indian Journal of Tuberculosis

COMPARATIVE ANALYSIS OF THE FREQUENCY AND STRUCTURE OF COMPLICATIONS OF THE BCG AND BCG-M TUBERCULOSIS VACCINE

Pozdnyakova, A. S. (2021) · Journal of the Grodno State Medical University · doi:10.25298/2221-8785-2021-19-1-71-76 · Cited by 1 · see citing works